Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin
1 other identifier
observational
50
1 country
1
Brief Summary
In most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. However, Metastatic cancer of unknown primary site (MUO) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. Most common metastatic sites include the liver, lymph nodes, lungs, and bones. 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2023
CompletedFirst Submitted
Initial submission to the registry
October 11, 2023
CompletedFirst Posted
Study publicly available on registry
October 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2023
CompletedOctober 17, 2023
October 1, 2023
3 months
October 11, 2023
October 11, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
primary tumor for metastasis of unknown origin
primary tumor for metastasis of unknown origin
one month
Interventions
detection of possible primary tumor
Eligibility Criteria
Age \> 18 years Patients with metastatic tumor. Primary site was not detected with other radiological examinations Both male and female.
You may qualify if:
- Age \> 18 years Patients with metastatic tumor. Primary site was not detected with other radiological examinations Both male and female.
You may not qualify if:
- Patients with known primary tumor Pregnancy. Age \< 18 years.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag university Hospital
Sohag, Egypt
Related Publications (2)
van der Strate I, Kazemzadeh F, Nagtegaal ID, Robbrecht D, van de Wouw A, Padilla CS, Duijts S, Esteller M, Greco FA, Pavlidis N, Qaseem A, Snaebjornsson P, van Zanten SV, Loef C. International consensus on the initial diagnostic workup of cancer of unknown primary. Crit Rev Oncol Hematol. 2023 Jan;181:103868. doi: 10.1016/j.critrevonc.2022.103868. Epub 2022 Nov 23.
PMID: 36435296BACKGROUNDKwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009 Mar;19(3):731-44. doi: 10.1007/s00330-008-1194-4. Epub 2008 Oct 17.
PMID: 18925401BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of nuclear medicine, faculty of medicine, Sohag university
Study Record Dates
First Submitted
October 11, 2023
First Posted
October 17, 2023
Study Start
September 15, 2023
Primary Completion
December 1, 2023
Study Completion
December 1, 2023
Last Updated
October 17, 2023
Record last verified: 2023-10